Cytokinetics (NASDAQ:CYTK) EVP Sells $270,795.00 in Stock

05 May 2026, 19:20 by Teresa Graham · The Cerbat Gem

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) EVP Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $77.37, for a total value of $270,795.00. Following the sale, the executive vice president directly owned 153,902 shares in the company, valued at $11,907,397.74. The trade was a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Fady Ibraham Malik also recently made the following trade(s):

On Tuesday, April 21st, Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $65.69, for a total value of $229,915.00.
On Tuesday, April 7th, Fady Ibraham Malik sold 4,500 shares of Cytokinetics stock. The shares were sold at an average price of $65.11, for a total value of $292,995.00.
On Tuesday, March 17th, Fady Ibraham Malik sold 12,033 shares of Cytokinetics stock. The shares were sold at an average price of $62.15, for a total value of $747,850.95.
On Monday, March 9th, Fady Ibraham Malik sold 2,907 shares of Cytokinetics stock. The stock was sold at an average price of $60.72, for a total value of $176,513.04.

Cytokinetics Price Performance

Shares of CYTK traded up $11.04 on Tuesday, hitting $77.09. The company’s stock had a trading volume of 18,074,833 shares, compared to its average volume of 2,059,842. The company has a market capitalization of $9.58 billion, a PE ratio of -11.81 and a beta of 0.38. Cytokinetics, Incorporated has a fifty-two week low of $29.31 and a fifty-two week high of $80.20. The company has a 50 day moving average price of $63.81 and a 200 day moving average price of $63.53.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) EPS for the quarter, hitting the consensus estimate of ($1.67). The business had revenue of $19.36 million during the quarter, compared to analyst estimates of $8.52 million. On average, equities analysts forecast that Cytokinetics, Incorporated will post -6.31 EPS for the current year.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: Topline pivotal ACACIA‑HCM Phase‑3 results met both dual primary endpoints (KCCQ and maximal exercise performance), a major clinical validation that expands the aficamten label opportunity and supports long‑term revenue potential. ACACIA‑HCM results
Positive Sentiment: Early U.S. commercial launch shows strong demand (over 275 HCPs prescribed an estimated ~680 patients in Q1) with net product revenues of $4.8M in the initial partial quarter; the EU approval and FDA supplemental NDA acceptance (PDUFA Nov 14, 2026) further de‑risk near‑term commercialization. Q1 results & business update
Positive Sentiment: Q1 revenue materially beat expectations ($19.36M actual vs. ~$8.52M expected); EPS matched consensus (‑$1.67). The revenue beat reflects product sales and supports upward re‑rating. Revenue beat
Positive Sentiment: Needham raised its price target to $102 and maintained a Buy, joining other analysts who have increased targets — a bullish signal from the sell side that can attract investor interest. Needham price target raise (Benzinga)
Neutral Sentiment: Company reported ~ $1.1B in cash, cash equivalents and investments as of March 31, providing runway for commercialization and ongoing trials; investors should watch burn vs. expected commercialization spend. Cash balance
Negative Sentiment: Cytokinetics announced a proposed underwritten offering of approximately $650M of common stock — likely dilutive and the main near‑term headwind; details (size, price, timing) will determine dilution and market impact. Proposed $650M offering
Negative Sentiment: EVP Andrew Callos sold 15,857 shares (Rule 10b5‑1 plan) — disclosed insider selling can be viewed negatively by some investors even if pre‑arranged. Insider sale filing

Analyst Upgrades and Downgrades

Several research analysts have recently commented on CYTK shares. Royal Bank Of Canada boosted their target price on Cytokinetics from $95.00 to $101.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Needham & Company LLC boosted their target price on Cytokinetics from $85.00 to $102.00 and gave the stock a “buy” rating in a report on Tuesday. Citizens Jmp boosted their target price on Cytokinetics from $88.00 to $96.00 and gave the stock a “market outperform” rating in a report on Wednesday, February 25th. Mizuho boosted their target price on Cytokinetics from $84.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, March 18th. Finally, UBS Group boosted their target price on Cytokinetics from $61.00 to $69.00 and gave the stock a “neutral” rating in a report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cytokinetics has an average rating of “Moderate Buy” and a consensus target price of $92.10.

View Our Latest Research Report on CYTK

Institutional Investors Weigh In On Cytokinetics

Several hedge funds and other institutional investors have recently made changes to their positions in CYTK. EverSource Wealth Advisors LLC increased its stake in shares of Cytokinetics by 723.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 673 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of Cytokinetics in the 4th quarter valued at $27,000. Kestra Advisory Services LLC acquired a new stake in shares of Cytokinetics in the 4th quarter valued at $29,000. Quarry LP acquired a new stake in shares of Cytokinetics in the 3rd quarter valued at $30,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Cytokinetics in the 4th quarter valued at $32,000.

About Cytokinetics

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.